Biotheranostics, Inc.
A Hologic Company



FIND YOUR

Finish

TO ANTI-ESTROGEN THERAPY

Individualized results help personalize care at any point in your treatment. Learn about the **Breast Cancer Index** test inside.

Breast Cancer Index® (BCI™) Test

For Patients

The Breast Cancer Index Test

A genomic test that provides two pieces of information to help inform discussions with your doctor on whether 5 vs 10 years of anti-estrogen therapy may be right for you:

1. Your risk of recurrence years 5-10 (reported as a percentage)
2. Whether continuing treatment for a full 10 years is likely to help reduce that risk (reported as a clear **YES** or **NO** answer)

The only test recognized by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the ASCO® Clinical Practice Guideline to predict whether you are likely to benefit from anti-estrogen therapy beyond 5 years.[8,9]

Now for patients earlier in their treatment plan, the BCI test can help provide greater Clarity from the Start.

Clarity from the Start™

- **POST**MENOPAUSAL: Anti-estrogen therapy: 10 years? 5 years? Even less?
- **PRE**MENOPAUSAL: Ovarian function suppression (OFS)? 5 vs. 10 years of anti-estrogen therapy?

Learn more at **breastcancerindex.com**

What is the *Right Length* of Anti-estrogen Treatment for You?

5

vs.

10

The **standard length** of anti-estrogen therapy is at least **5 years.**[1] But some women **may benefit from 10 years**.[2-7]

While continuing treatment beyond 5 years helps some women with ealy-stage, hormone receptor-positive (HR+) breast cancer lower their risk of recurrence, **not all women benefit.**[2-7]

Only the Breast Cancer Index test is recognized by national oncology guidelines to predict if ***you*** are likely to benefit from continuing anti-estrogen therapy beyond 5 years.[8,9]

When You Can See the Finish Line, *Every Day Feels Worth It*

Between hot flashes, fatigue, joint pains, and other potential side effects from anti-estrogen therapy,[2,10,11] you may wonder,

"**How much longer until I feel like myself again?**"

You Could Be Close and *Not Know It**

> *When I got my results, I could have danced on the ceiling.*
>
> *I was so happy to know that I wasn't going to have to take this medicine that had really changed my life in ways I didn't like.*
>
> **– Mary, Breast cancer survivor & BCI patient**

Please review your BCI test results with your healthcare provider to make an informed decision regarding your treatment plan.

Getting the Test is *Simple*

Start by asking your doctor if the test is right for you.

The Breast Cancer Index test may be ordered for women:

- Diagnosed with early-stage, HR+ breast cancer and lymph node-negative or lymph node-positive with up to 3 positive lymph nodes
- On tamoxifen or an aromatase inhibitor, regardless of menopausal status
- Who have not had a metastatic recurrence

What to Expect Once Your Doctor has Ordered the Test

1. Tissue from your original tumor sample will be sent to our lab. No additional procedures are needed.
2. Your doctor will receive your BCI test results in one clear and easy-to-understand report. The results will help you and your provider decide the appropriate length of anti-estrogen treatment for you.

Scan the QR code or visit **breastcancerindex.com/explore-report** to learn more about BCI results.

Starting the *Conversation*

Take this guide with you to your next doctor's appointment.

- What is my individual risk of having a recurrence after 5 years? What is this based on?
- Can I lower my risk of cancer coming back? If so, how?
- How long will I need to take my anti-estrogen medication? Is this based on my risk or whether longer treatment is likely to help?
- What are the potential side effects of my medication?
- Are there any long-term health concerns related to taking anti-estrogen therapy for an extended period of time?
- How do we decide if the potential benefits of anti-estrogen therapy beyond 5 years outweigh the potential risks?
- Am I an appropriate candidate for the Breast Cancer Index test?



Contact the Patient Services Team

We are committed to ensuring all eligible patients have access to BCI testing.

- The BCI test is covered by Medicare with no co-pay or deductible for patients who meet the coverage criteria.†
- The BCI test is covered by many insurance plans. As with all health-related visits, tests, or procedures, you should be aware of your deductibles, co-pays, and co-insurance responsibilities.
- Through our Access First program, financial assistance is also available for those who qualify.

Contact our Patient Services Team directly to discuss your insurance coverage so that you are prepared when your doctor orders your Breast Cancer Index test.



(844) 319-8111



Patient.Services@hologic.com

Learn more at
breastcancerindex.com

Ready to #findyourfinish?
Ask your doctor about the BCI test.

*** Breast Cancer Index Intended Use and Limitations**

The Breast Cancer Index (BCI) test is a polymerase chain reaction (PCR) based gene expression test which analyses two gene expression signatures from formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained sections on glass slides via macrodissection. The gene expression signatures include the Molecular Grade Index (MGI), a five-gene signature, and the HOXB13/IL17BR (H/I), a two-gene ratio signature. The test is indicated for use in women diagnosed with early-stage hormone receptor-positive (HR+), lymph node-negative (N0) or lymph node-positive (N1; 1-3 positive nodes) invasive breast cancer. The BCI test provides a quantitative estimate of overall (years 0-10) and late (years 5-10) distant recurrence risk and informs the likelihood of endocrine therapy benefit for women who are distant recurrence-free.

BCI results are adjunctive to the ordering physician's workup; treatment decisions require correlation with all other clinical findings. This test was developed, and its performance characteristics determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes and should not be regarded as experimental or investigational. How this information is used to guide patient care is the responsibility of the treating provider. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 to perform high complexity clinical laboratory testing.

† Visit breastcancerindex.com/resources to see coverage criteria under the Local Coverage Determination.

References: 1. Burstein HJ, et al. J Clin Oncol. 2014;32:2255-2269. **2.** Davies C, et al. Lancet Oncol. 2013;381:805-816. **3.** Gray R, et al. J Clin Oncol. 2013;31:(suppl;abstr 5). **4.** Jakesz R, et al. J Natl Cancer Inst. 2007;99:1845-1853. **5.** Goss PE, et al. J Natl Cancer Inst. 2005;97:1262-1271. **6.** Goss PE, et al. N Engl J Med. 2003;349. **7.** Mamounas EP, et al. Clin Cancer Res. 2024; 30(9):1984-1991. **8.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed June 16, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. **9.** Andre F, et al. J Clin Oncol. 2022;40(16):1816-1837. Referenced with permission from the American Society of Clinical Oncology (ASCO®) Clinical Practice Guideline Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer. © American Society of Clinical Oncology. 2026. All rights reserved. To view the most recent and complete version of the guideline, go online to https://ascopubs.org/jco/special/guidelines [ascopubs.org]. ASCO makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way. **10.** Goss PE, et al. N Engl J Med. 2016;375:209-219. **11.** Jennifer Carr. Side Effects of Hormonal Therapy for Breast Cancer. BreastCancer.org. Updated June 11, 2026. Accessed June 16, 2026. https://www.breastcancer.org/treatment/hormonal-therapy/side-effects.

MRK-PP001-001 Rev 2.0 © 2026 Hologic, Inc. All rights reserved. Hologic, Biotheranostics, Breast Cancer Index, BCI, Clarity from the Start, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks are the property of their respective owners.